A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549 · Recruiting

Last updated 2026-05-28

This clinical trial is testing different investigational treatments in children and adolescents who are overweight or have obesity to see how they respond to each option.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) screening study

Participants 125 people Planned (estimated).

Who can join Ages 6–17 · all sexes

Timeline Started 2024-11 · est. completion 2027-03

Where 50 sites · Brazil, Israel, Italy, Japan, Mexico, Poland, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06672549 ↗

Description as written by the study sponsor.

The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally. ISA specific interventions will be listed in the ISA.
Placebo Drug

Administered orally. ISA specific interventions will be listed in the ISA.

Main thing measured	Number of Participants Allocated to Each ISA
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06672549 ↗